Latest news with #ZuelligPharma
Bangkok Post
4 days ago
- Health
- Bangkok Post
Zuellig Pharma Strengthens Healthcare Access in Thailand
As Thailand navigates a shifting healthcare landscape marked by ageing populations and rising rates of chronic illnesses, Zuellig Pharma—a leading healthcare solutions provider in Asia—is doubling down on its commitment to the Kingdom. With over 75 years of local presence and more than a century of experience across Asia, the company's recent THB 130 million investment in expanding its distribution centre in Samut Prakan is more than an infrastructure upgrade—it's a bold signal of long-term partnership with Thailand's health system. Zuellig Pharma's purpose is clear: to make healthcare more accessible. From digital innovations and cold chain logistics to local partnerships with institutions such as Thammasat University Hospital, the company is working to bridge the healthcare access gap, particularly in areas such as weight-related conditions and chronic disease management. These efforts are central to its wider mission in the region. Investing in Innovation for a Healthier Thailand Thailand is moving quickly to approve innovative treatments and therapies, creating a fertile ground for strategic alliances. Zuellig Pharma has responded by forging partnerships with global biopharmaceutical companies to bring cutting-edge treatments to Thai patients faster. These include solutions supporting chronic disease management and advanced treatments for complex conditions. Through its commercial and distribution services, Zuellig Pharma plays a key role in connecting life-changing therapies with local healthcare providers, accelerating patient access and supporting healthcare professionals with essential tools and knowledge. Building Infrastructure to Reach the Hardest-to-Reach The expanded Samut Prakan distribution centre now boasts a storage capacity of 1,800 pallets, a dedicated ultra-low temperature freezer room (-20°C to -30°C) for specialty medicines, and advanced temperature control systems. This upgrade reflects Zuellig Pharma's readiness to support a new generation of temperature-sensitive, high-value medicines and vaccines. Sustainability and safety are also at the heart of the investment. Fire protection systems, sustainable packaging such as the proprietary eZCooler, and automated defrost systems contribute to efficient, secure, and environmentally conscious operations—ensuring safe last-mile deliveries to even the most remote communities. Supporting Thai People through Public–Private Partnerships Central to Zuellig Pharma's approach is collaboration. The company has formed long-term partnerships with Thai universities and healthcare institutions to promote innovation and workforce development. A standout example is its alliance with Action4Diabetes (A4D), a non-profit working across seven Southeast Asian countries, including Thailand, to close care gaps for children with Type 1 diabetes. Since 2017, Zuellig Pharma has supported A4D with logistics, supply chain expertise, and regional distribution capabilities—most recently delivering life-saving care packs to families affected by the March 2025 Myanmar earthquake, in collaboration with local charity City Love & Hope Foundation. During the COVID-19 pandemic, Zuellig Pharma provided essential logistics services by helping to distribute millions of vaccine doses nationwide. This reflects its agility and deep-rooted commitment to supporting Thailand in times of need. Thailand's Role in Zuellig Pharma's ASEAN Growth Strategy With its dynamic healthcare system, forward-looking regulations, and strategic location, Thailand plays a vital role in Zuellig Pharma's regional vision. 'Thailand has always been a cornerstone of Zuellig Pharma's presence in Asia,' said John Graham, Group CEO of Zuellig Pharma. 'With its dynamic healthcare landscape, progressive regulatory environment, and deep talent pool, the country plays a pivotal role in shaping our regional growth strategy. Our continued investment here reflects not only our confidence in Thailand's long-term potential, but also our commitment to ensuring that innovative, life-changing medicines are accessible to every community — no matter how remote.' A Long-Term Vision for Healthcare Access Zuellig Pharma's presence in Thailand is more than a business strategy—it's a commitment to sustainable healthcare progress. From pioneering supply chain innovation to supporting local healthcare partners, the company remains a trusted ally in the country's journey toward health equity. As the region prepares for a future shaped by ageing populations and increasing demand for complex therapies, Zuellig Pharma stands ready to meet the challenge—ensuring that no patient is left behind.
Bangkok Post
7 days ago
- Business
- Bangkok Post
Zuellig Pharma Expands Thai Distribution Centre with THB 130m
Zuellig Pharma, a leading healthcare solutions provider in Asia, has announced a THB 130 million (US$4 million) investment to expand its pharmaceutical distribution centre in Bang Sao Thong District, Samut Prakan. This strategic move will significantly enhance the facility's pharmaceutical-grade logistics capabilities and strengthen Thailand's healthcare supply chain. The upgraded distribution hub features high-precision temperature control systems that comply with global Good Distribution Practice (GDP) standards, ensuring the integrity of life-saving medicines and vaccines during storage and delivery. With a storage capacity of 1,800 pallets and a dedicated low-temperature freezer room (-20°C to -30°C), the facility will support the growing demand for biologics, vaccines, and specialty medicines across the country. 'This investment marks a significant milestone in our journey as an integrated healthcare solutions company,' said John Graham, CEO of Zuellig Pharma. 'It allows us to meet rising healthcare needs in Thailand while reinforcing our regional distribution network.' Smart systems within the facility include automated temperature monitoring, emergency power backups, a certified NFPA 13 fire suppression system, and a fire-resistant structure built to FM 4800 and FM 4881 standards. These upgrades aim to deliver consistent quality, safety, and reliability throughout the supply chain. Zuellig Pharma Thailand also integrates sustainable practices with eZCooler reusable cold chain packaging, energy-efficient air conditioning, and smart LED lighting to reduce carbon emissions. 'The expansion reaffirms our commitment to making healthcare accessible,' said Pucknalin Bulakul, Managing Director of Zuellig Pharma Thailand. 'By ensuring timely delivery and uncompromised product quality, we are supporting better patient outcomes across the country.'
Bloomberg
09-07-2025
- Business
- Bloomberg
Zuellig Pharma on Tariff Threats
The China Show John Graham, CEO at Zuellig Pharma, says he expects most industry peers to be scrambling to understand the potential impact of US tariffs on supply chains. He speaks exclusively with Haslinda Amin on "Bloomberg: The China Show" from the Techcombank Investment Summit 2025. (Source: Bloomberg)
Korea Herald
08-07-2025
- Health
- Korea Herald
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
The campaign aims to enhance the understanding of obesity as a chronic disease and solutions to help manage the disease among Thais and healthcare providers. BANGKOK, July 8, 2025 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions provider in Asia, is organizing the "Obesity is a Disease" seminar as part of its "Reduce Size, Reduce Disease" awareness campaign. The seminar aims to reinforce the message that obesity is more than a cosmetic concern, and solutions to manage the disease among healthcare practitioners. It is a silent national public health crisis that significantly impacts individuals living with obesity, particularly women. Studies have highlighted the urgency of addressing rising obesity rates, as the 2014 National Health Examination Survey found that 37.5% of Thais aged 15 and over were obese (BMI > 25), with the rate for women at 41.8%. By 2023, this figure had climbed to 45% for women, compared to 38% for men 1. Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast and endometrial cancer. The "Reduce Size, Reduce Disease" campaign therefore aims not only to encourage behavioral change but also to dismantle the social stigma that treats obesity as a personal failure, fostering an understanding of it as a chronic disease that requires proper care. Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, said, "Zuellig Pharma is dedicated to enhancing the health of the Thai people by championing the understanding that obesity is not about aesthetics, and instead is a chronic disease requiring holistic treatment. We believe that equitable access to healthcare is the foundation of a sustainable society, and our 'Reduce Size, Reduce Disease' campaign is a direct reflection of this commitment, moving beyond promoting new treatment innovations to providing comprehensive knowledge and practical guidance on weight management. This seminar reflects our dedication in driving change and shifting the societal narrative on obesity from judgment to understanding and care, for the long-term health for everyone." The "Obesity is a Disease" seminar involved healthcare practitioners from all over Thailand, who are committed to educating and deepening their understanding of obesity as a disease among Thais; and constantly find ways and solutions to help fight the disease. Prof. Dr. Rungsima Wanitphakdeedecha, Head of the Department of Dermatology, Chief of the Division of Dermatologic Surgery, and Director of the Siriraj Skin Laser Center at the Faculty of Medicine Siriraj Hospital, Mahidol University, explained, "At its heart, the "Reduce Size, Reduce Disease" campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being, focusing on safe and effective health management to prevent comorbidities linked to obesity. It shows that when we truly invest in our own well-being, long-term health will be sustainable." Asst. Prof. Dr. Mart Maiprasert, Dean and Chairman of the Graduate Program Executive Committee at the College of Integrative Medicine (CIM), said "Effective weight management today hinges on multiple factors, including a strong partnership between patients and medical experts, proper lifestyle habits, good nutrition, and consistent exercise. Together, these elements form the foundation of what we call the 'X2' approach, which emphasizes that being healthy is not achieved through dieting or exercise alone but through a sustainable, balanced integration of both for lasting results." Master Dr. Rassapoom Sumaetheiwit, a specialist in dermatology and aesthetic medicine, added, "Helping our clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient to tailor the most appropriate and safe treatment plan. This integrated approach ensures that losing weight is not merely about aesthetics, but about achieving genuine health and physical balance. Our commitment is to provide this level of comprehensive, personalized care to deliver safe and sustainable long-term results." The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, while also spotlighting the urgent public health challenge that obesity represents in Thailand. About Zuellig Pharma Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Yahoo
08-07-2025
- Health
- Yahoo
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
The campaign aims to enhance the understanding of obesity as a chronic disease and solutions to help manage the disease among Thais and healthcare providers. BANGKOK, July 8, 2025 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions provider in Asia, is organizing the "Obesity is a Disease" seminar as part of its "Reduce Size, Reduce Disease" awareness campaign. The seminar aims to reinforce the message that obesity is more than a cosmetic concern, and solutions to manage the disease among healthcare practitioners. It is a silent national public health crisis that significantly impacts individuals living with obesity, particularly women. Studies have highlighted the urgency of addressing rising obesity rates, as the 2014 National Health Examination Survey found that 37.5% of Thais aged 15 and over were obese (BMI > 25), with the rate for women at 41.8%. By 2023, this figure had climbed to 45% for women, compared to 38% for men1. Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast and endometrial cancer. The "Reduce Size, Reduce Disease" campaign therefore aims not only to encourage behavioral change but also to dismantle the social stigma that treats obesity as a personal failure, fostering an understanding of it as a chronic disease that requires proper care. Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, said, "Zuellig Pharma is dedicated to enhancing the health of the Thai people by championing the understanding that obesity is not about aesthetics, and instead is a chronic disease requiring holistic treatment. We believe that equitable access to healthcare is the foundation of a sustainable society, and our 'Reduce Size, Reduce Disease' campaign is a direct reflection of this commitment, moving beyond promoting new treatment innovations to providing comprehensive knowledge and practical guidance on weight management. This seminar reflects our dedication in driving change and shifting the societal narrative on obesity from judgment to understanding and care, for the long-term health for everyone." The "Obesity is a Disease" seminar involved healthcare practitioners from all over Thailand, who are committed to educating and deepening their understanding of obesity as a disease among Thais; and constantly find ways and solutions to help fight the disease. Prof. Dr. Rungsima Wanitphakdeedecha, Head of the Department of Dermatology, Chief of the Division of Dermatologic Surgery, and Director of the Siriraj Skin Laser Center at the Faculty of Medicine Siriraj Hospital, Mahidol University, explained, "At its heart, the "Reduce Size, Reduce Disease" campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being, focusing on safe and effective health management to prevent comorbidities linked to obesity. It shows that when we truly invest in our own well-being, long-term health will be sustainable." Asst. Prof. Dr. Mart Maiprasert, Dean and Chairman of the Graduate Program Executive Committee at the College of Integrative Medicine (CIM), said "Effective weight management today hinges on multiple factors, including a strong partnership between patients and medical experts, proper lifestyle habits, good nutrition, and consistent exercise. Together, these elements form the foundation of what we call the 'X2' approach, which emphasizes that being healthy is not achieved through dieting or exercise alone but through a sustainable, balanced integration of both for lasting results." Master Dr. Rassapoom Sumaetheiwit, a specialist in dermatology and aesthetic medicine, added, "Helping our clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient to tailor the most appropriate and safe treatment plan. This integrated approach ensures that losing weight is not merely about aesthetics, but about achieving genuine health and physical balance. Our commitment is to provide this level of comprehensive, personalized care to deliver safe and sustainable long-term results." The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, while also spotlighting the urgent public health challenge that obesity represents in Thailand. About Zuellig Pharma Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world. For more information, visit References 1. View original content to download multimedia: SOURCE Zuellig Pharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
